In a significant move to enhance the resilience of the U.S. healthcare system, Trump has signed multiple executive orders aimed at bolstering the stockpile of critical medicines and their active pharmaceutical ingredients. This initiative, which includes the operationalization of the Strategic Active Pharmaceutical Ingredient Reserve (SAPIR), aims to ensure a reliable supply chain for essential medications amid concerns over global supply chain vulnerabilities. The actions come as part of a broader effort to reduce dependence on foreign suppliers, particularly from China, and to promote American manufacturing in the pharmaceutical sector. Industry leaders, including representatives from Phlow Corp., have expressed support for these measures, highlighting their potential to improve health security.